Johnson & Johnson (NYSE:JNJ) ranks among the best most active stocks to buy right now. On March 13, Johnson & Johnson ...
The new, full-range TECNIS Odyssey intraocular lens aims to reduce dependence on glasses, with strong performance in any ...
Enhancement coverage applies within 24 months of the original procedure for refractive and premium lens pathways. Beyond this ...
My New York City practice has been a refractive-only practice for more than 25 years, offering the full range of FDA-approved ...
On March 19, Barclays raised its price recommendation on Johnson & Johnson (NYSE:JNJ) to $234 from $217. It kept an Equal ...
The Conversation reports cataract surgery is safe and common, with over 90% achieving 20/20 vision, but patients need to ...
SpyGlass Pharma Inc., which is promising an intraocular lens that will reshape the treatment of glaucoma, emerged from its ...
HHS’ Office of the Inspector General issued a favorable result regarding a proposal to offer discounts to certain ASCs in ...
The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.
Johnson & Johnson (NYSE: JNJ) announced that it received FDA approval for its Tecnis PureSee intraocular lens (IOL) for ...
The FDA approved the Tecnis PureSee IOL, an extended depth of focus IOL for cataract surgery, according to a press release ...
FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results